Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: A randomized, controlled trial

Kerri Winters-Stone, Jessica Dobek, Lillian Nail, Jill Bennett, Michael C. Leo, Arpana Naik, Anna Schwartz

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Targeted exercise training could reduce risk factors for fracture and obesity-related diseases that increase from breast cancer treatment, but has not been sufficiently tested. We hypothesized that progressive, moderate-intensity resistance + impact training would increase or maintain hip and spine bone mass, lean mass and fat mass and reduce bone turnover compared to controls who participated in a low-intensity, non-weight bearing stretching program. We conducted a randomized, controlled trial in 106 women with early stage breast cancer who were >1 year post-radiation and/or chemotherapy, 50 years of age at diagnosis and postmenopausal, free from osteoporosis and medications for bone loss, resistance and impact exercise naïve, and cleared to exercise by a physician. Women were randomly assigned to participate in 1 year of thrice-weekly progressive, moderate-intensity resistance + impact (jump) exercise or in a similar frequency and length control program of progressive, low-intensity stretching. Primary endpoints were bone mineral density (BMD; g/cm2) of the hip and spine and whole body bone-free lean and fat mass (kg) determined by DXA and biomarkers of bone turnover-serum osteocalcin (ng/ml) and urinary deoxypyrodiniline cross-links (nmol/mmolCr). Women in the resistance + impact training program preserved BMD at the lumbar spine (0.47 vs. -2.13%; P = 0.001) compared to controls. The resistance + impact group had a smaller increase in osteocalcin (7.0 vs. 27%, P = 0.03) and a larger decrease in deoxypyrodinoline (-49.9 vs. -32.6%, P = 0.06) than controls. Increases in lean mass from resistance + impact training were greatest among women currently taking aromatase inhibitors compared to controls not on this therapy (P = 0.01). Our combined program of resistance + impact exercise reduced risk factors for fracture among postmenopausal breast cancer survivors (BCS) and may be particularly relevant for BCS on aromatase inhibitors (AIs) because of the additional benefit of exercise on muscle mass that could reduce falls.

Original languageEnglish (US)
Pages (from-to)447-456
Number of pages10
JournalBreast Cancer Research and Treatment
Volume127
Issue number2
DOIs
StatePublished - Jun 2011

Fingerprint

Resistance Training
Survivors
Randomized Controlled Trials
Exercise
Breast Neoplasms
Bone and Bones
Muscles
Aromatase Inhibitors
Spine
Bone Remodeling
Osteocalcin
Fats
Pelvic Bones
Postmenopausal Osteoporosis
Bone Density
Hip
Obesity
Biomarkers
Radiation
Physicians

Keywords

  • Aromatase inhibitors
  • Body composition
  • Neoplasms
  • Osteoporosis
  • Resistance exercise

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors : A randomized, controlled trial. / Winters-Stone, Kerri; Dobek, Jessica; Nail, Lillian; Bennett, Jill; Leo, Michael C.; Naik, Arpana; Schwartz, Anna.

In: Breast Cancer Research and Treatment, Vol. 127, No. 2, 06.2011, p. 447-456.

Research output: Contribution to journalArticle

Winters-Stone, Kerri ; Dobek, Jessica ; Nail, Lillian ; Bennett, Jill ; Leo, Michael C. ; Naik, Arpana ; Schwartz, Anna. / Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors : A randomized, controlled trial. In: Breast Cancer Research and Treatment. 2011 ; Vol. 127, No. 2. pp. 447-456.
@article{1514052392b84d1c9e02c361cca0d590,
title = "Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: A randomized, controlled trial",
abstract = "Targeted exercise training could reduce risk factors for fracture and obesity-related diseases that increase from breast cancer treatment, but has not been sufficiently tested. We hypothesized that progressive, moderate-intensity resistance + impact training would increase or maintain hip and spine bone mass, lean mass and fat mass and reduce bone turnover compared to controls who participated in a low-intensity, non-weight bearing stretching program. We conducted a randomized, controlled trial in 106 women with early stage breast cancer who were >1 year post-radiation and/or chemotherapy, 50 years of age at diagnosis and postmenopausal, free from osteoporosis and medications for bone loss, resistance and impact exercise na{\"i}ve, and cleared to exercise by a physician. Women were randomly assigned to participate in 1 year of thrice-weekly progressive, moderate-intensity resistance + impact (jump) exercise or in a similar frequency and length control program of progressive, low-intensity stretching. Primary endpoints were bone mineral density (BMD; g/cm2) of the hip and spine and whole body bone-free lean and fat mass (kg) determined by DXA and biomarkers of bone turnover-serum osteocalcin (ng/ml) and urinary deoxypyrodiniline cross-links (nmol/mmolCr). Women in the resistance + impact training program preserved BMD at the lumbar spine (0.47 vs. -2.13{\%}; P = 0.001) compared to controls. The resistance + impact group had a smaller increase in osteocalcin (7.0 vs. 27{\%}, P = 0.03) and a larger decrease in deoxypyrodinoline (-49.9 vs. -32.6{\%}, P = 0.06) than controls. Increases in lean mass from resistance + impact training were greatest among women currently taking aromatase inhibitors compared to controls not on this therapy (P = 0.01). Our combined program of resistance + impact exercise reduced risk factors for fracture among postmenopausal breast cancer survivors (BCS) and may be particularly relevant for BCS on aromatase inhibitors (AIs) because of the additional benefit of exercise on muscle mass that could reduce falls.",
keywords = "Aromatase inhibitors, Body composition, Neoplasms, Osteoporosis, Resistance exercise",
author = "Kerri Winters-Stone and Jessica Dobek and Lillian Nail and Jill Bennett and Leo, {Michael C.} and Arpana Naik and Anna Schwartz",
year = "2011",
month = "6",
doi = "10.1007/s10549-011-1444-z",
language = "English (US)",
volume = "127",
pages = "447--456",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors

T2 - A randomized, controlled trial

AU - Winters-Stone, Kerri

AU - Dobek, Jessica

AU - Nail, Lillian

AU - Bennett, Jill

AU - Leo, Michael C.

AU - Naik, Arpana

AU - Schwartz, Anna

PY - 2011/6

Y1 - 2011/6

N2 - Targeted exercise training could reduce risk factors for fracture and obesity-related diseases that increase from breast cancer treatment, but has not been sufficiently tested. We hypothesized that progressive, moderate-intensity resistance + impact training would increase or maintain hip and spine bone mass, lean mass and fat mass and reduce bone turnover compared to controls who participated in a low-intensity, non-weight bearing stretching program. We conducted a randomized, controlled trial in 106 women with early stage breast cancer who were >1 year post-radiation and/or chemotherapy, 50 years of age at diagnosis and postmenopausal, free from osteoporosis and medications for bone loss, resistance and impact exercise naïve, and cleared to exercise by a physician. Women were randomly assigned to participate in 1 year of thrice-weekly progressive, moderate-intensity resistance + impact (jump) exercise or in a similar frequency and length control program of progressive, low-intensity stretching. Primary endpoints were bone mineral density (BMD; g/cm2) of the hip and spine and whole body bone-free lean and fat mass (kg) determined by DXA and biomarkers of bone turnover-serum osteocalcin (ng/ml) and urinary deoxypyrodiniline cross-links (nmol/mmolCr). Women in the resistance + impact training program preserved BMD at the lumbar spine (0.47 vs. -2.13%; P = 0.001) compared to controls. The resistance + impact group had a smaller increase in osteocalcin (7.0 vs. 27%, P = 0.03) and a larger decrease in deoxypyrodinoline (-49.9 vs. -32.6%, P = 0.06) than controls. Increases in lean mass from resistance + impact training were greatest among women currently taking aromatase inhibitors compared to controls not on this therapy (P = 0.01). Our combined program of resistance + impact exercise reduced risk factors for fracture among postmenopausal breast cancer survivors (BCS) and may be particularly relevant for BCS on aromatase inhibitors (AIs) because of the additional benefit of exercise on muscle mass that could reduce falls.

AB - Targeted exercise training could reduce risk factors for fracture and obesity-related diseases that increase from breast cancer treatment, but has not been sufficiently tested. We hypothesized that progressive, moderate-intensity resistance + impact training would increase or maintain hip and spine bone mass, lean mass and fat mass and reduce bone turnover compared to controls who participated in a low-intensity, non-weight bearing stretching program. We conducted a randomized, controlled trial in 106 women with early stage breast cancer who were >1 year post-radiation and/or chemotherapy, 50 years of age at diagnosis and postmenopausal, free from osteoporosis and medications for bone loss, resistance and impact exercise naïve, and cleared to exercise by a physician. Women were randomly assigned to participate in 1 year of thrice-weekly progressive, moderate-intensity resistance + impact (jump) exercise or in a similar frequency and length control program of progressive, low-intensity stretching. Primary endpoints were bone mineral density (BMD; g/cm2) of the hip and spine and whole body bone-free lean and fat mass (kg) determined by DXA and biomarkers of bone turnover-serum osteocalcin (ng/ml) and urinary deoxypyrodiniline cross-links (nmol/mmolCr). Women in the resistance + impact training program preserved BMD at the lumbar spine (0.47 vs. -2.13%; P = 0.001) compared to controls. The resistance + impact group had a smaller increase in osteocalcin (7.0 vs. 27%, P = 0.03) and a larger decrease in deoxypyrodinoline (-49.9 vs. -32.6%, P = 0.06) than controls. Increases in lean mass from resistance + impact training were greatest among women currently taking aromatase inhibitors compared to controls not on this therapy (P = 0.01). Our combined program of resistance + impact exercise reduced risk factors for fracture among postmenopausal breast cancer survivors (BCS) and may be particularly relevant for BCS on aromatase inhibitors (AIs) because of the additional benefit of exercise on muscle mass that could reduce falls.

KW - Aromatase inhibitors

KW - Body composition

KW - Neoplasms

KW - Osteoporosis

KW - Resistance exercise

UR - http://www.scopus.com/inward/record.url?scp=79958210804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958210804&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1444-z

DO - 10.1007/s10549-011-1444-z

M3 - Article

C2 - 21424279

AN - SCOPUS:79958210804

VL - 127

SP - 447

EP - 456

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -